Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy specifically mentioned for the eradication of **Helicobacter pylori (H. pylori)** infection. It consists of three antibiotics (amoxicillin, levofloxacin, and tinidazole) and a proton pump inhibitor (omeprazole). **Amoxicillin** is a beta-lactam antibiotic that works by inhibiting bacterial cell wall synthesis. **Levofloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA topoisomerase II, effective against various bacteria including H. pylori. **Omeprazole** is a proton pump inhibitor that reduces stomach acid production. **Tinidazole** is a nitroimidazole antibiotic, similar to metronidazole. This combination is typically used in a **sequential therapy** regimen for H. pylori. One described regimen involves administering omeprazole and amoxicillin for the first 5 days, followed by omeprazole, levofloxacin, and tinidazole for the next 5 days. Studies mentioned in the search results indicate high eradication rates with this approach, potentially higher than clarithromycin-containing sequential therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amoxicillin + Levofloxacin + Omeprazole + Tinidazole.